Bacterial prostatitis

World Journal of Urology

Volumn 31, Issue 4, 2013, Pages 711-716

  Wagenlehner, Florian M E ^a   Pilatz, Adrian ^a   Bschleipfer, Thomas ^a   Diemer, Thorsten ^a   Linn, Thomas ^a   Meinhardt, Andreas ^a   Schagdarsurengin, Undraga ^a   Dansranjavin, Temujin ^a   Schuppe, Hans Christian ^a   Weidner, Wolfgang ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Bacterial prostatitis; Biofilm; Pharmacology; Prostatitis syndrome; Virulence factors

Indexed keywords

ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ACUTE DISEASE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CHRONIC DISEASE; CLASSIFICATION; DISEASE COURSE; HUMAN; MALE; MICROBIOLOGY; PROSTATITIS;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHRONIC DISEASE; DISEASE PROGRESSION; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MALE; PROSTATITIS;

EID: 84881053678     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-013-1055-x     Document Type: Article

References (38)

1. NIDDK (1995) Workshop Committee of the National Institute of Diabetes and Digestive and Kidney Disease. Chronic Prostatitis Workshop, Bethesda, MD, 7-8 Dec 1995.
2. Krieger JN, Nyberg L Jr, Nickel JC (1999) NIH consensus definition and classification of prostatitis. JAMA 282(3): 236-237.
3. Schaeffer AJ (1999) Prostatitis: US perspective. Int J Antimicrob Agents 11(3-4): 205-211 (discussion 13-6).
4. Schaeffer AJ (2006) Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med 355(16): 1690-1698.
5. Lee SW, Cheah PY, Liong ML, Yuen KH, Schaeffer AJ, Propert K et al (2007) Demographic and clinical characteristics of chronic prostatitis: prospective comparison of the University of Sciences Malaysia Cohort with the United States National Institutes of Health Cohort. J Urol 177(1): 153-157 (discussion 8).
6. Millan-Rodriguez F, Palou J, Bujons-Tur A, Musquera-Felip M, Sevilla-Cecilia C, Serrallach-Orejas M et al (2006) Acute bacterial prostatitis: two different sub-categories according to a previous manipulation of the lower urinary tract. World J Urol 24(1): 45-50.
7. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM (2011) Complications after prostate biopsy: data from SEER-Medicare. J Urol 186(5): 1830-1834.
8. Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH et al (2010) Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 183(3): 963-968.
9. Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schroder FH, Roobol MJ (2012) Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 61(6): 1110-1114.
10. Wagenlehner F, van Oostrum E, Tenke P, Tandogdu Z, Cek M, Grabe M, Naber KG, Weidner W, Bjerklund-Johansen T (2013) Infective complications after prostate biopsy: outcome of the Global Prevalence of Infections in Urology (GPIU) prostate biopsy study 2010 and 2011, a prospective, multinational, multicenter study. Eur Urol 63(3): 521-527.
11. Steensels D, Slabbaert K, De Wever L, Vermeersch P, van Poppel H, Verhaegen J (2012) Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy-should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 18(6): 575-581.
12. Taylor AK, Zembower TR, Nadler RB, Scheetz MH, Cashy JP, Bowen D et al (2012) Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol 187(4): 1275-1279.
13. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE (2010) Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 10(1): 43-50.
14. Clemens JQ, Meenan RT, O'Keeffe Rosetti MC, Gao SY, Calhoun EA (2005) Incidence and clinical characteristics of National Institutes of Health type III prostatitis in the community. J Urol 174(6): 2319-2322.
15. Yoon BI, Kim S, Han DS, Ha US, Lee SJ, Kim HW et al (2012) Acute bacterial prostatitis: how to prevent and manage chronic infection? J Infect Chemother 18(4): 444-450.
16. Krieger JN, Dobrindt U, Riley DE, Oswald E (2011) Acute Escherichia coli prostatitis in previously health young men: bacterial virulence factors, antimicrobial resistance, and clinical outcomes. Urology 77(6): 1420-1425.
17. Ruiz J, Simon K, Horcajada JP, Velasco M, Barranco M, Roig G et al (2002) Differences in virulence factors among clinical isolates of Escherichia coli causing cystitis and pyelonephritis in women and prostatitis in men. J Clin Microbiol 40(12): 4445-4449.
18. Weidner W, Schiefer HG, Krauss H, Jantos C, Friedrich HJ, Altmannsberger M (1991) Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1, 461 patients. Infection 19(Suppl 3): S119-S125.
19. Bundrick W, Heron SP, Ray P, Schiff WM, Tennenberg AM, Wiesinger BA et al (2003) Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology 62(3): 537-541.
20. Krieger JN, Ross SO, Limaye AP, Riley DE (2005) Inconsistent localization of gram-positive bacteria to prostate-specific specimens from patients with chronic prostatitis. Urology 66(4): 721-725.
21. Nickel JC, Olson ME, Costerton JW (1991) Rat model of experimental bacterial prostatitis. Infection 19(Suppl 3): S126-S130.
22. Soto SM, Smithson A, Martinez JA, Horcajada JP, Mensa J, Vila J (2007) Biofilm formation in uropathogenic Escherichia coli strains: relationship with prostatitis, urovirulence factors and antimicrobial resistance. J Urol 177(1): 365-368.
23. Mazzoli S, Cai T, Rupealta V, Gavazzi A, Castricchi Pagliai R, Mondaini N et al (2007) Interleukin 8 and anti-Chlamydia trachomatis mucosal IgA as urogenital immunologic markers in patients with C. trachomatis prostatic infection. Eur Urol 51(5): 1385-1393.
24. Horcajada JP, Vilana R, Moreno-Martinez A, Alvarez-Vijande R, Bru C, Bargallo X et al (2003) Transrectal prostatic ultrasonography in acute bacterial prostatitis: findings and clinical implications. Scand J Infect Dis 35(2): 114-120.
25. Meares EM, Stamey TA (1968) Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 5(5): 492-518.
26. Nickel JC, Shoskes D, Wang Y, Alexander RB, Fowler JE Jr, Zeitlin S et al (2006) How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol 176(1): 119-124.
27. Weidner W, Ludwig M, Brahler E, Schiefer HG (1999) Outcome of antibiotic therapy with ciprofloxacin in chronic bacterial prostatitis. Drugs 58(Suppl 2): 103-106.
28. Grabe M, Bjerklund-Johansen TE, Botto H, Wullt B, Cek M, Naber KG et al (2012) Guidelines on urological infections. European Association of Urology Guidelines, 2012 edition European Association of Urology, Arnhem, The Netherlands, pp 1-110.
29. Ludwig M, Schroeder-Printzen I, Schiefer HG, Weidner W (1999) Diagnosis and therapeutic management of 18 patients with prostatic abscess. Urology 53(2): 340-345.
30. Chou YH, Tiu CM, Liu JY, Chen JD, Chiou HJ, Chiou SY et al (2004) Prostatic abscess: transrectal color Doppler ultrasonic diagnosis and minimally invasive therapeutic management. Ultrasound Med Biol 30(6): 719-724.
31. Hua LX, Zhang JX, Wu HF, Zhang W, Qian LX, Xia GW et al (2005) The diagnosis and treatment of acute prostatitis: report of 35 cases. Zhonghua Nan Ke Xue 11(12): 897-899.
32. Stamey TA, Meares EM Jr, Winningham DG (1970) Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid. J Urol 103(2): 187-194.
33. Stamey TA, Bushby SR, Bragonje J (1973) The concentration of trimethoprim in prostatic fluid: nonionic diffusion or active transport? J Infect Dis 128(Suppl): 686-692.
34. Gasser T, Larsen EH, Dorflinger T, Madsen PO (1986) The influence of various body fluids and pH on E. coli MIC of quinolone derivatives. In: Weidner W (ed) Therapy of prostatitis experimental and clinical data. Zuckschwerdt, Munich, pp 50-53.
35. Wagenlehner FM, Weidner W, Sorgel F, Naber KG (2005) The role of antibiotics in chronic bacterial prostatitis. Int J Antimicrob Agents 26(1): 1-7.
36. Perletti G, Wagenlehner FM, Naber KG, Magri V (2009) Enhanced distribution of fourth-generation fluoroquinolones in prostatic tissue. Int J Antimicrob Agents 33(3): 206-210.
37. Wagenlehner F, Pilatz A, Bschleipfer T, Diemer T, Weidner W (2013) Prostatitis syndrome. In: Hamdy FEI (ed) The Oxford textbook of urological surgery. Oxford University Press, Oxford.
38. Magri V, Montanari E, Skerk V, Markotic A, Marras E, Restelli A et al (2011) Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction. Asian J Androl 13(6): 819-827.